Monarch Capital Management Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,559 shares of the biopharmaceutical company’s stock after purchasing an additional 3,975 shares during the quarter. Gilead Sciences accounts for approximately 1.7% of Monarch Capital Management Inc.’s investment portfolio, making the stock its 27th largest position. Monarch Capital Management Inc.’s holdings in Gilead Sciences were worth $4,501,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of GILD. Penserra Capital Management LLC lifted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences in the second quarter worth $147,000. Harel Insurance Investments & Financial Services Ltd. lifted its position in Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV bought a new stake in Gilead Sciences in the second quarter worth $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in Gilead Sciences in the second quarter worth $172,000. 76.23% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently issued reports on the company. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Thursday. Maxim Group set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, December 11th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and raised their price target for the stock from $73.25 to $73.77 in a research report on Monday, November 13th. Finally, Mizuho raised their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $85.11.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.75 earnings per share. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.75%. Gilead Sciences’s dividend payout ratio is currently 23.69%.
In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 494,999 shares of company stock worth $37,404,139. Insiders own 1.30% of the company’s stock.
WARNING: This story was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2017/12/17/monarch-capital-management-inc-acquires-3975-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.